文章来源于微信公众号：医道社皮肤新前沿，想浏览更多皮肤专业文章请搜索前往！

Adults on dupilumab for severe chronic rhinosinusitis with nasal polyps had better outcomes than those who used omalizumab, ...

Biological drugs have improved the lives of many people with severe asthma. However, a new study from Karolinska Institutet ...

来自德国吕贝克大学和柏林夏里特医院的Prof. Enno Schmidt及Prof. Margitta Worm团队开展了一项针对大疱性类天疱疮(BP)的II/III期临床 ...

智通财经APP获悉，再生元(REGN.US)和赛诺菲(SNY.US)联合开发的重磅疗法Dupixent(dupilumab)获美国FDA批准，用于治疗大疱性类天疱疮(BP)成人患者。根据新闻稿，Dupixent是获美国FDA批准的首款BP疗法。据悉， ...

A new study published in the Journal of American Medical Association showed that dupilumab (Dupixent), used for treating ...

Dupilumab was approved by the FDA to treat bullous pemphigoid, that demonstrated its efficacy in achieving sustained disease ...

This study reveals that dupilumab is associated with a modestly increased risk of developing psoriasis, highlighting the ...

The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as the first targeted therapy for bullous ...

Bio-Thera Solutions, Ltd., a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and ...

Bio-Thera Solutions & SteinCares expand partnership to commercialize biosimilars to treat inflammatory diseases across Latin America: Guangzhou, China Thursday, June 26, 2025, 12: ...

Key findings of subgroup analyses included an observed increased psoriasis risk in patients without atopic comorbidities (HR 1.42, 95% CI 1.06-1.89) and those with pretreatment immunoglobulin E (IgE) ...